Blueprint for fusion

Blueprint and Rockefeller find a fusion protein driver of a rare liver cancer

Blueprint Medicines Corp. (NASDAQ:BPMC) and researchers at The Rockefeller University are ramping up their collaboration to develop inhibitors of a disease-driving fusion protein found in all patients with fibrolamellar carcinoma, a rare subtype of hepatocellular carcinoma (HCC) for which the only available treatment option is surgical resection.

The partners joined forces in 2014, after

Read the full 539 word article

User Sign In